Insider Trading disclosures for Entero Therapeutics Inc.
The latest disclosure was made by Sarah M. Romano in Entero Therapeutics Inc. where a trade of 727
Common Stock done at an average price of $0.6
was reported to US exchanges on Jan. 6, 2025.
Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company.
A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).
| Client Name |
Client Category |
Action |
Reported to Exchange |
Quantity |
Post Transaction Holding |
Traded % |
Avg. Price |
Value |
Security Type |
|
Sarah M. Romano
|
Chief Financial Officer |
|
06 Jan 2025 |
727 |
17,287
(0%)
|
0%
|
0.6 |
465
|
Common Stock |
|
Sarah M. Romano
|
Chief Financial Officer |
|
09 Oct 2024 |
476 |
18,014
(0%)
|
0%
|
0.4 |
212
|
Common Stock |
|
James Sapirstein
|
Director, Chairman and CEO |
|
02 Jul 2024 |
1,289 |
35,816
(0%)
|
0%
|
1.1 |
1,379
|
Common Stock |
|
Sarah M. Romano
|
Chief Financial Officer |
|
02 Jul 2024 |
621 |
18,490
(0%)
|
0%
|
1.1 |
664
|
Common Stock |
|
Chaitan S. Khosla
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
11 Jun 2024 |
24,889 |
24,889
(0%)
|
0%
|
|
0
|
Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges